Eli Lilly and Company has announced positive topline results from two Phase 3 clinical trials, ACHIEVE-2 and ACHIEVE-5, evaluating orforglipron, its oral GLP-1 receptor agonist, in adults with type 2 diabetes. In ACHIEVE-2, orforglipron demonstrated superior glycemic control compared to dapagliflozin, an SGLT-2 inhibitor, reducing A1C by up to 1.7% versus 0.8% with dapagliflozin. ACHIEVE-5 assessed orforglipron versus placebo in patients receiving titrated insulin glargine, with orforglipron achieving an additional A1C reduction of up to 2.1%. Both trials met primary and key secondary endpoints at 40 weeks, showing significant A1C reduction, weight loss, and improvements in cardiovascular risk factors. The safety profile was consistent with previous studies, with gastrointestinal-related adverse events being the most common and generally mild-to-moderate in severity. The detailed results of these trials will be presented at a future medical meeting and published in a peer-reviewed journal.